Biotin anti-human CD154 Antibody anti-CD154 - 24-31,BioLegend,310814
Additional reported applications (for the relevant formats) include: immunofluorescence microscopy1,3and blocking of T cell-dependent B cell differentiation1,2,4,5. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 310812). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 310828) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Host
Mouse
Reactivity
Human
Application
FC - Quality tested
Platform ID
BAB360372669

BioLegend
Contact
Tel: 1-858-455-9588
Fax: +49 (4131) 7023913
Email:
Product Specifications
Scientific Background
Specifications
NameBiotin anti-human CD154 Antibody anti-CD154 - 24-31
Cat. No.310814
HostMouse
RRIDAB_492966 (BioLegend Cat. No. 310814)
IsotypeMouse IgG1, κ
ReactivityHuman
ApplicationFC - Quality tested
ClonalityMonoclonal
Clone Number24-31
Concentration0.5 mg/ml
TargetCD154
PurityThe antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.Do not freeze.
Regulatory StatusResearch Use Only
Scientific Background
CD154 (CD40 ligand) is also known as CD40L, gp39, TRAP and T-BAM. CD40 ligand is a 32-39 kD type II transmembrane glycoprotein. It is a member of the TNF superfamily and is expressed on activated T cells. It has been reported to be important for B cell costimulation following binding of its receptor, CD40. Additionally, binding of CD40L to CD40 on B cells promotes the secretion of immunoglobulin and Ig isotype switching. CD40L is also involved in the regulation of cytokine production by T cells.
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
